false
0001821825
0001821825
2025-11-03
2025-11-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report
(Date of earliest event reported): November
3, 2025
Organon
& Co.
(Exact name of registrant
as specified in its charter)
| Delaware |
|
001-40235 |
|
46-4838035 |
| (State or other jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
| incorporation) |
|
| |
|
| |
|
|
|
|
30
Hudson Street, Floor
33,
Jersey City,
NJ |
|
|
|
07302 |
(Address and principal executive
offices) |
|
|
|
(Zip Code) |
| Registrant’s telephone number, including area code: (551)
430-6900 |
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of
each class |
|
Trading
Symbol(s) |
|
Name of
each exchange on which registered |
| Common
Stock, par value $0.01 per share |
|
OGN |
|
NYSE |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers. |
On November 3, 2025, Grace Puma informed Organon
& Co. (the “Company”) that she will not stand for re-election at the Company’s 2026 Annual Meeting
of Stockholders (the “2026 Annual Meeting”). Ms. Puma has served as a member of the Board of Directors (the “Board”)
of the Company since 2021 and currently serves as a member of the Talent Committee of the Board. Ms. Puma will continue to serve as a
director and in her committee role until the 2026 Annual Meeting.
Ms. Puma’s departure is not due to any disagreement
between her and the Company, its management, the Board or any committee thereof, or any matter relating to the Company’s operations,
policies or practices.
| Exhibit No. |
Description |
| |
|
| 104 | The Cover Page of this Current Report on Form 8-K, formatted
in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
| |
Organon & Co. |
| |
|
| |
By: |
/s/ Kirke Weaver |
| |
|
Name: |
Kirke Weaver |
| |
|
Title: |
General Counsel |
Dated: November 7, 2025